Compare MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MicroSectors FANG and Innovation 3X Leveraged ETN vs Merck & Co., Inc. — how do they compare? MicroSectors FANG and Innovation 3X Leveraged ETN trades at $32.13, while Merck & Co., Inc. trades at $130.44 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while MicroSectors FANG and Innovation 3X Leveraged ETN pays none, and Merck & Co., Inc. is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals.
| FNGU | MRK | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $36.15 | $131.84 |
52-Week Low | $13.73 | $77.60 |
Market Cap | — | $321.77B |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNGU (MicroSectors FANG+ 3X Leveraged ETN) trades at $32.45, down 3.71% today, reflecting the inherent volatility of leveraged products. Technical indicators show a bullish moving average trend but neutral oscillators, with RSI levels suggesting overbought conditions. Recent news highlights significant downside volatility, including a 16% single-session drop on June 5, 2026, underscoring the risks of 3x leverage on tech stocks.
The outlook for FNGU remains highly speculative, driven by Nasdaq-100 volatility rather than company fundamentals. Investment opportunities exist for aggressive traders betting on tech rallies, but risks include amplified losses during market downturns and structural decay from daily rebalancing. Caution is warranted given the product's design for short-term trading.
MRK trades at $133.6, up 2.06% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average support. Recent earnings have consistently beaten estimates, with Q3 2026 expected at $2.27 EPS. The company's acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, while revenue growth remains steady at $65.01B in 2025.
MRK presents a positive outlook with a consensus price target of $140.36, indicating potential upside. Strong institutional buying and a 67.57% buy rating from analysts support bullish sentiment. Risks include rising debt-to-asset ratios and competitive pressures in the pharma sector. The dividend yield of $0.85 per half-year adds income appeal for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
